U.S. Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type, By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
U.S. Inflammatory Bowel Disease Treatment Market Growth & Trends
The U.S. inflammatory bowel disease treatment market size is anticipated to reach USD 14.1 billion by 2030 and is projected to grow at a CAGR of 2.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of ulcerative colitis and Crohn’s disease across the U.S. is anticipated to drive market growth in the forecast period. A combination of genetic predisposition, immune system dysfunction, environmental factors, gut microbiota imbalance, and lifestyle factors likely influence the development of inflammatory bowel disease (IBD). According to an article published in 2023, inflammatory bowel disease is a relatively common chronic condition affecting >0.7% of Americans and is most prevalent in the Northeastern region. This growing patient population necessitates advanced treatment options, driving the market growth.
The Crohn's & Colitis Foundation works toward enhancing product development to improve the quality of life of patients suffering from inflammatory bowel illnesses. The foundation has launched these ventures, a dedicated funding system to support product-oriented research and development.
In September 2023, Takeda announced the FDA's acceptance of the biologics license application (BLA) for the subcutaneous administration of ENTYVIO (vedolizumab) to treat Crohn’s disease. Regulatory approvals pave the way for new medications, biologics, and devices to enter the market. This can lead to a broader range of treatment options for patients with IBD, potentially improving treatment outcomes and quality of life.
U.S. Inflammatory Bowel Disease Treatment Market Report Highlights
U.S. Inflammatory Bowel Disease Treatment Market Growth & Trends
The U.S. inflammatory bowel disease treatment market size is anticipated to reach USD 14.1 billion by 2030 and is projected to grow at a CAGR of 2.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of ulcerative colitis and Crohn’s disease across the U.S. is anticipated to drive market growth in the forecast period. A combination of genetic predisposition, immune system dysfunction, environmental factors, gut microbiota imbalance, and lifestyle factors likely influence the development of inflammatory bowel disease (IBD). According to an article published in 2023, inflammatory bowel disease is a relatively common chronic condition affecting >0.7% of Americans and is most prevalent in the Northeastern region. This growing patient population necessitates advanced treatment options, driving the market growth.
The Crohn's & Colitis Foundation works toward enhancing product development to improve the quality of life of patients suffering from inflammatory bowel illnesses. The foundation has launched these ventures, a dedicated funding system to support product-oriented research and development.
In September 2023, Takeda announced the FDA's acceptance of the biologics license application (BLA) for the subcutaneous administration of ENTYVIO (vedolizumab) to treat Crohn’s disease. Regulatory approvals pave the way for new medications, biologics, and devices to enter the market. This can lead to a broader range of treatment options for patients with IBD, potentially improving treatment outcomes and quality of life.
U.S. Inflammatory Bowel Disease Treatment Market Report Highlights
- Based on type, the Crohn’s disease segment dominated the market in 2023 with the largest revenue share. This large share is due to the requirement for more treatment options and advancements due to the chronic inflammatory nature of Crohn’s disease, which affects the gastrointestinal tract and causes symptoms such as abdominal pain, diarrhea, weight loss, and fatigue.
- On the other hand, the ulcerative colitis segment is expected to register the fastest CAGR during the forecast period, owing to its increasing incidence rate.
- Based on drug class, the TNF inhibitors segment accounted for the largest market revenue share in 2023 due to their effectiveness in managing the symptoms and reducing inflammation.
- Based on route of administration, the injectable segment held the largest market share in 2023. Injectable medications, such as biologics and biosimilars, are designed to target specific proteins or cells involved in the inflammatory process of inflammatory bowel disease.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Drug Class
1.2.3. Route of Administration
1.2.4. Distribution Channel
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type
2.2.2. Drug Class
2.2.3. Route of Administration
2.2.4. Distribution Channel
2.3. Competitive Insights
CHAPTER 3. U.S. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. U.S. Inflammatory Bowel Disease Treatment Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
CHAPTER 4. U.S. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET: TYPE ESTIMATES & TREND ANALYSIS
4.1. Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Inflammatory Bowel Disease Treatment Market by Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
4.4.1. Crohn's Disease
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.2. Ulcerative Colitis
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
CHAPTER 5. U.S. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET: DRUG CLASS ESTIMATES & TREND ANALYSIS
5.1. Drug Class Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. U.S. Inflammatory Bowel Disease Treatment Market by Drug Class Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
5.4.1. Aminosalicylates
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.2. Corticosteroids
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.3. TNF Inhibitors
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.4. IL Inhibitors
5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.5. Anti-integrin
5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.6. JAK Inhibitors
5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.7. Others
5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
CHAPTER 6. U.S. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET: ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS
6.1. Route of Administration Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. U.S. Inflammatory Bowel Disease Treatment Market by Route of Administration Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
6.4.1. Oral
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.2. Injectable
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
CHAPTER 7. U.S. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
7.1. Distribution Channel Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. U.S. Inflammatory Bowel Disease Treatment Market by Distribution Channel Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
7.4.1. Hospital Pharmacy
7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
7.4.2. Retail Pharmacy
7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
7.4.3. Online Pharmacy
7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
CHAPTER 8. U.S. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET: REGION ESTIMATES & TREND ANALYSIS
8.1. Regional Market Share, 2023 & 2030
8.2. U.S. Inflammatory Bowel Disease Treatment Market by Region Outlook
8.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
8.3.1. West
8.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
8.3.2. Midwest
8.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
8.3.3. Northeast
8.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
8.3.4. Southwest
8.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
8.3.5. Southeast
8.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
9.3.1. List of key distributors and channel partners
9.3.2. Key customers
9.3.3. Key company heat map analysis, 2023
9.4. Company Profiles
9.4.1. Biogen
9.4.1.1. Company overview
9.4.1.2. Financial performance
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.4.2. Novartis AG
9.4.2.1. Company overview
9.4.2.2. Financial performance
9.4.2.3. Product benchmarking
9.4.2.4. Strategic initiatives
9.4.3. Eli Lilly & Company
9.4.3.1. Company overview
9.4.3.2. Financial performance
9.4.3.3. Product benchmarking
9.4.3.4. Strategic initiatives
9.4.4. UCB S.A.
9.4.4.1. Company overview
9.4.4.2. Financial performance
9.4.4.3. Product benchmarking
9.4.4.4. Strategic initiatives
9.4.5. Celltrion Inc.
9.4.5.1. Company overview
9.4.5.2. Financial performance
9.4.5.3. Product benchmarking
9.4.5.4. Strategic initiatives
9.4.6. Merck & Co., Inc.
9.4.6.1. Company overview
9.4.6.2. Financial performance
9.4.6.3. Product benchmarking
9.4.6.4. Strategic initiatives
9.4.7. Johnson & Johnson Services, Inc.
9.4.7.1. Company overview
9.4.7.2. Financial performance
9.4.7.3. Product benchmarking
9.4.7.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Drug Class
1.2.3. Route of Administration
1.2.4. Distribution Channel
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type
2.2.2. Drug Class
2.2.3. Route of Administration
2.2.4. Distribution Channel
2.3. Competitive Insights
CHAPTER 3. U.S. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. U.S. Inflammatory Bowel Disease Treatment Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
CHAPTER 4. U.S. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET: TYPE ESTIMATES & TREND ANALYSIS
4.1. Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Inflammatory Bowel Disease Treatment Market by Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
4.4.1. Crohn's Disease
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.2. Ulcerative Colitis
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
CHAPTER 5. U.S. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET: DRUG CLASS ESTIMATES & TREND ANALYSIS
5.1. Drug Class Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. U.S. Inflammatory Bowel Disease Treatment Market by Drug Class Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
5.4.1. Aminosalicylates
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.2. Corticosteroids
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.3. TNF Inhibitors
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.4. IL Inhibitors
5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.5. Anti-integrin
5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.6. JAK Inhibitors
5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.7. Others
5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
CHAPTER 6. U.S. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET: ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS
6.1. Route of Administration Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. U.S. Inflammatory Bowel Disease Treatment Market by Route of Administration Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
6.4.1. Oral
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.2. Injectable
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
CHAPTER 7. U.S. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
7.1. Distribution Channel Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. U.S. Inflammatory Bowel Disease Treatment Market by Distribution Channel Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
7.4.1. Hospital Pharmacy
7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
7.4.2. Retail Pharmacy
7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
7.4.3. Online Pharmacy
7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
CHAPTER 8. U.S. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET: REGION ESTIMATES & TREND ANALYSIS
8.1. Regional Market Share, 2023 & 2030
8.2. U.S. Inflammatory Bowel Disease Treatment Market by Region Outlook
8.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
8.3.1. West
8.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
8.3.2. Midwest
8.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
8.3.3. Northeast
8.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
8.3.4. Southwest
8.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
8.3.5. Southeast
8.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
9.3.1. List of key distributors and channel partners
9.3.2. Key customers
9.3.3. Key company heat map analysis, 2023
9.4. Company Profiles
9.4.1. Biogen
9.4.1.1. Company overview
9.4.1.2. Financial performance
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.4.2. Novartis AG
9.4.2.1. Company overview
9.4.2.2. Financial performance
9.4.2.3. Product benchmarking
9.4.2.4. Strategic initiatives
9.4.3. Eli Lilly & Company
9.4.3.1. Company overview
9.4.3.2. Financial performance
9.4.3.3. Product benchmarking
9.4.3.4. Strategic initiatives
9.4.4. UCB S.A.
9.4.4.1. Company overview
9.4.4.2. Financial performance
9.4.4.3. Product benchmarking
9.4.4.4. Strategic initiatives
9.4.5. Celltrion Inc.
9.4.5.1. Company overview
9.4.5.2. Financial performance
9.4.5.3. Product benchmarking
9.4.5.4. Strategic initiatives
9.4.6. Merck & Co., Inc.
9.4.6.1. Company overview
9.4.6.2. Financial performance
9.4.6.3. Product benchmarking
9.4.6.4. Strategic initiatives
9.4.7. Johnson & Johnson Services, Inc.
9.4.7.1. Company overview
9.4.7.2. Financial performance
9.4.7.3. Product benchmarking
9.4.7.4. Strategic initiatives
LIST OF TABLES
Table 1 List of abbreviations
Table 2 U.S. inflammatory bowel disease treatment market, by type, 2018 - 2030 (USD Million)
Table 3 U.S. inflammatory bowel disease treatment market, by drug class, 2018 - 2030 (USD Million)
Table 4 U.S. inflammatory bowel disease treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 5 U.S. inflammatory bowel disease treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 6 U.S. inflammatory bowel disease treatment market, by region, 2018 - 2030 (USD Million)
Table 1 List of abbreviations
Table 2 U.S. inflammatory bowel disease treatment market, by type, 2018 - 2030 (USD Million)
Table 3 U.S. inflammatory bowel disease treatment market, by drug class, 2018 - 2030 (USD Million)
Table 4 U.S. inflammatory bowel disease treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 5 U.S. inflammatory bowel disease treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 6 U.S. inflammatory bowel disease treatment market, by region, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. inflammatory bowel disease treatment market: market outlook
Fig. 9 U.S. Inflammatory bowel disease treatment competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 U.S. inflammatory bowel disease treatment market driver impact
Fig. 14 U.S. inflammatory bowel disease treatment market restraint impact
Fig. 15 U.S. inflammatory bowel disease treatment market: Type movement analysis
Fig. 16 U.S. inflammatory bowel disease treatment market: Type outlook and key takeaways
Fig. 17 Crohn's Disease market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 Ulcerative Colitis estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 U.S. inflammatory bowel disease treatment market: Drug class movement analysis
Fig. 20 U.S. inflammatory bowel disease treatment market: Drug class outlook and key takeaways
Fig. 21 Aminosalicylates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Corticosteroids market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 TNF inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 IL inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Anti-integrin market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 JAK inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 U.S. inflammatory bowel disease treatment market: Route of administration movement analysis
Fig. 28 U.S. inflammatory bowel disease treatment market: Route of administration outlook and key takeaways
Fig. 29 Oral market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Injectable market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 U.S. inflammatory bowel disease treatment market: Distribution channel movement analysis
Fig. 32 U.S. inflammatory bowel disease treatment market: Distribution channel outlook and key takeaways
Fig. 33 Hospital pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Retail pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Online pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 U.S. inflammatory bowel disease treatment market: Regional movement analysis
Fig. 37 U.S. inflammatory bowel disease treatment market: Regional outlook and key takeaways
Fig. 38 West market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. inflammatory bowel disease treatment market: market outlook
Fig. 9 U.S. Inflammatory bowel disease treatment competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 U.S. inflammatory bowel disease treatment market driver impact
Fig. 14 U.S. inflammatory bowel disease treatment market restraint impact
Fig. 15 U.S. inflammatory bowel disease treatment market: Type movement analysis
Fig. 16 U.S. inflammatory bowel disease treatment market: Type outlook and key takeaways
Fig. 17 Crohn's Disease market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 Ulcerative Colitis estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 U.S. inflammatory bowel disease treatment market: Drug class movement analysis
Fig. 20 U.S. inflammatory bowel disease treatment market: Drug class outlook and key takeaways
Fig. 21 Aminosalicylates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Corticosteroids market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 TNF inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 IL inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Anti-integrin market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 JAK inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 U.S. inflammatory bowel disease treatment market: Route of administration movement analysis
Fig. 28 U.S. inflammatory bowel disease treatment market: Route of administration outlook and key takeaways
Fig. 29 Oral market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Injectable market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 U.S. inflammatory bowel disease treatment market: Distribution channel movement analysis
Fig. 32 U.S. inflammatory bowel disease treatment market: Distribution channel outlook and key takeaways
Fig. 33 Hospital pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Retail pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Online pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 U.S. inflammatory bowel disease treatment market: Regional movement analysis
Fig. 37 U.S. inflammatory bowel disease treatment market: Regional outlook and key takeaways
Fig. 38 West market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)
